Latest News

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight.

And that reason is different (but related) for these two auto-making giants.

Wall Street's first prominent stock-split stock of 2025 makes for a no-brainer buy, while an artificial intelligence (AI)-driven highflier may be on shaky ground.

Two businesses built to thrive in every economic environment.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock

A unique occurrence for Wall Street's benchmark index has historically left investors seeing green.

Wireless telecommunications provider U.S. Cellular (NYSE:USM) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

Health insurance company Cigna (NYSE:CI) will be reporting earnings tomorrow morning. Here’s what to expect.

Modular flooring manufacturer Interface (NASDAQ:TILE) will be reporting results tomorrow morning. Here’s what investors should know.

Alphabet Inc-CL A (NASDAQ:GOOGL): A GARP Investment Opportunity

Live sports and TV streaming service fuboTV (NYSE:FUBO) will be reporting results tomorrow before the bell. Here’s what to look for.

Fast-food chain Wendy’s (NASDAQ:WEN) will be announcing earnings results tomorrow before the bell. Here’s what to expect.

Manufacturing services provider Proto Labs (NYSE:PRLB) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

Healthcare services provider BrightSpring Health Services (NASDAQ:BTSG) will be announcing earnings results tomorrow before market open. Here’s what to expect.

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

We got a huge data dump on Wednesday, including the first estimate of Q1 GDP, which came in marginally negative at -0.3%. Net exports and government subtracted a total of 5.08%, with exports making up the majority of that.

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Palantir CEO Alex Karp defends Silicon Valley's right to open discourse and partnership with government in his new book, amid expanding government presence and upcoming earnings report.